• PP 2 (AG 1879): Mechanism and Evidence Scope

  2026-10-15

  PP 2, also known as AG 1879, is described by APExBIO as a potent Src-family tyrosine-kinase inhibitor, with reported biochemical IC50 values of 4 nM for Lck and 5 nM for Fyn. The same product information associates it with reduced proliferation and invasion in U251 glioma cells, inhibition of early T-cell signal transduction, and effects on Src phosphorylation and reflex potentiation in rats. Because no identity-matched paper, methods, sample sizes, or uncertainty estimates are available here, these statements should be treated as supplier-reported evidence rather than an independently verified literature record.

• Protease Inhibitor Cocktail: Evidence and Scope

  2026-10-14

  The APExBIO Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) is documented as a multi-inhibitor formulation intended to limit degradation of proteins during extraction and sample preparation. Its stated components target several protease classes, while the absence of EDTA is presented as relevant to applications in which divalent cations or metal-dependent enzymes must be preserved. These claims describe formulation rationale and intended measurement contexts, not independently demonstrated product performance: no identity-matched research study, comparative outcome, sample size, or uncertainty estimate is available in the cited materials.

• Nigericin Sodium Salt: Evidence Scope

  2026-10-14

  Nigericin sodium salt is documented by an APExBIO product listing as a potassium ionophore associated conceptually with K+/H+ exchange, membrane ion transport and cytoplasmic pH changes. Because no matched research paper is available, claims involving lead-ion transport, platelet aggregation or cellular bioenergetics remain catalog-level descriptions rather than independently assessed findings.

• TPA Signaling: Evidence and Applicability Boundaries

  2026-10-13

  An evidence-focused overview of 12-O-tetradecanoyl phorbol-13-acetate (TPA), its conceptual role in protein kinase C and ERK/MAPK signaling research, and the limits of connecting pharmacological pathway activation with findings from a separate CD16-shedding immunotherapy study.

• Immunoproteasome Probes: What the Study Shows

  2026-10-13

  Loy and Trader describe a caged bioluminescent activity-based probe intended to selectively report immunoproteasome activity. The study’s contribution is primarily methodological: it presents a probe concept and assay framework, with reported compatibility in cellular assays and a tissue-mimic context. The supplied evidence does not establish clinical utility, in vivo performance, or quantitative selectivity across disease models. HBTU is relevant only as a general peptide-synthesis reagent; the supplied study does not document APExBIO HBTU use.

• BNNC and Hypoxia-Selective Cyclin K Therapy

  2026-10-12

  The supplied Journal of Medicinal Chemistry study presents BNNC as a hypoxia-responsive photomolecular glue intended to combine Cyclin K degradation with phototherapy. Its reported breast-cancer-cell and in vivo findings support a preclinical proof of concept, but the available evidence does not establish clinical efficacy, long-term selectivity, or the role of mitochondrial membrane potential.

• Aureonitol, ROS, and Mitochondrial Readouts

  2026-10-12

  The supplied 2026 study reports herbicidal activity for aureonitol from Chaetomium coarctatum NEAU-Z3, associated with reactive oxygen species accumulation, redox disruption, and transcriptomic changes. A JC-1 mitochondrial membrane potential assay could conceptually address ΔΨm, but the study summary does not report JC-1 measurements or establish mitochondrial depolarization as aureonitol’s direct target.

• ARCA and Synthetic mRNA: Evidence Boundaries

  2026-10-11

  Anti Reverse Cap Analog is a supplier-described orientation-biased Cap 0 analog for synthetic mRNA. Its conceptual relevance to translation initiation is clear, but the cited oligodendrocyte study supports synthetic modified mRNA reprogramming broadly, not ARCA-specific performance or clinical efficacy.

• PRINT: RNA-Mediated Safe-Harbor Transgene Insertion

  2026-10-10

  The reference study introduces PRINT, an RNA-mediated strategy that uses avian R2 retroelement proteins to direct transgene synthesis into a multicopy human safe-harbor locus. Its findings support a potentially lower-mutagenesis alternative to DNA donor delivery, while remaining limited to biochemical assays and cultured human cells rather than clinical validation.

• Cy3 Maleimide in H1 Replication-Stress Research

  2026-10-09

  Cy3 maleimide is a thiol-reactive fluorescent probe with potential conceptual value for visualizing labeled proteins, peptides, oligonucleotides, or biomolecular assemblies. The supplied H1 study, however, used site-specific photocrosslinking rather than Cy3 maleimide. This overview separates the published evidence on phosphorylated linker histone H1 from supplier-reported dye properties, then examines how fluorescence could complement—not replace—interaction mapping, biochemical assays, and cellular rescue experiments.

• Anti Reverse Cap Analog: Evidence and Limits

  2026-10-09

  Anti Reverse Cap Analog (ARCA), also called 3´-O-Me-m7G(5')ppp(5')G, is an orientation-selective cap analog used in synthetic mRNA research. Foundational studies support its ability to reduce reverse incorporation of cap analogs and improve translation in defined experimental systems. However, reported benefits are context-dependent and should not be treated as a universal twofold increase in protein output. The strongest evidence concerns cap orientation and translation initiation; evidence for mRNA stability enhancement, therapeutic performance, or superiority in mRNA therapeutics research is more conditional because sequence design, nucleotide chemistry, purification, delivery, and innate immune sensing also contribute. The supplied TCAIM study is not evidence about ARCA and should not be used to support claims about synthetic mRNA.

• CFDA SE Cell Tracer Kit: Product Overview

  2026-10-08

  The CFDA SE Cell Tracer Kit is a commercial fluorescent labeling product containing carboxyfluorescein diacetate succinimidyl ester (CFDA SE). Its documented scope includes conceptual cell tracking, cell proliferation studies, and lineage-tracing research, but no matched peer-reviewed paper evidence was supplied.

• Nicotinamide Riboside Chloride in RGC Research

  2026-10-08

  A source-grounded overview of Nicotinamide Riboside Chloride (NIAGEN), NAD+ metabolism, and retinal ganglion cell research, distinguishing published RGC differentiation findings from unconfirmed translational hypotheses.

• SARS-CoV-2 Variant Shifts in ACE2 Usage

  2026-10-07

  Shukla et al. developed a multiplexed pseudotyped-virus assay that measures how SARS-CoV-2 spike variants interact with diverse ACE2 orthologs and human sequence variants in parallel. Their results show modest changes in human ACE2 compatibility but substantially different compatibility patterns across animal ACE2 proteins, providing evidence that viral evolution can reshape potential host range.

• Nystatin (Fungicidin): Five Evidence Questions

  2026-10-07

  A source-grounded overview of Nystatin’s ergosterol-targeting principle, the evidence for moxidectin synergy, and the limits of translating laboratory and mouse findings into broader antifungal claims.

7900 records 1/527 page Next 12345 下5页 Last page